MedPath

Correlation of dermatoscopic features of vitiligo with the disease activity and response to treatment

Not yet recruiting
Conditions
Vitiligo,
Registration Number
CTRI/2020/06/025516
Lead Sponsor
Department of Dermatology
Brief Summary

Vitiligo has an acquired disorder of hypopigmentation. Many markers of disease activity In vitiligo has been described previously. Dermatoscopy is a non invasive tool which allows us to view structures are macroscopically invisible to the naked eye.  But there has not been any longitudinal prospective study which sequentially describes the dermatoscopic markers of activity and repigmentation in active vitiligo. Therefore this observational study is being conducted to assess the dermatoscopic markers of vitiligo and to correlate the same with disease activity and treatment response.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Patients with clinical diagnosis of segmental or non segmental vitiligo 2.
  • Patients with active disease 3.
  • Patients initiated on medical management.
Exclusion Criteria
  • Patients with stable disease 2.
  • Patients who receive phototherapy or surgical management 3.
  • Patients who did not give consent for participation in the study.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To sequentially determine the dermatoscopic features of vitiligoBaseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks
Secondary Outcome Measures
NameTimeMethod
1. To correlate dermatoscopic features with disease activity assessed by means of VIDA and VASI2. To correlate dermatoscopic features of repigmentation with treatment modality used

Trial Locations

Locations (1)

PGIMER, Chandigarh

🇮🇳

Chandigarh, CHANDIGARH, India

PGIMER, Chandigarh
🇮🇳Chandigarh, CHANDIGARH, India
Vinay K
Principal investigator
8872993222
vinay.keshavmurthy@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.